Aventis, development phase drugs

Chapters 5-7 illustrate the potential for commercial development of a nimiber of promising organometallics. Dubar and Biot describe in detail the mechanism of action of ferroquine, an antimalarial agent in phase II clinical trials at Sanofi Aventis. He shows that this drug can be linked to an oxidizing stress effect and plays a key role in the inhibition of the reinvasion stage of merozoites. This is an important mechanistic discovery that may provide a source of inspiration. 

---